Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thorough QTc Study of KRP-S124 in Healthy Participants
NCT07919314Phase 1Recruiting
- Sponsor
- Kyorin Pharmaceutical
- Start
- Oct 2026
- Primary completion
- Feb 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of KRP-S124 (5 arms), sponsored by Kyorin Pharmaceutical. Primary endpoint: Placebo-corrected Change From Baseline in Fridericia's Corrected QT interval. Started Oct 2026; status: recruiting.
02
Drugs
KRP-S124
Beyond the preview
Go deeper on NCT07919314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07919314.